Recent Updates
Recently added Catalysts

Sevirumab

Phase 1

Cytomegalovirus Infections | Small molecule | Infectious Disease |Novartis AG|Last Updated: Jun 24, 2005

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment -

FDA Designations

No designations recorded

Clinical trial landscape

Sevirumab · 2 trials · 3 indications

Phase 1 2
NCT00002016A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV RetinitisCytomegalovirus Retinitis
COMPLETED- Analytics
NCT00002268A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or ViruriaCytomegalovirus Infections
COMPLETED- Analytics
PHASE1COMPLETED
A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis
Cytomegalovirus Retinitis
NCT00002016-
Unlock trial analytics
PHASE1COMPLETED
A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria
Cytomegalovirus Infections
NCT00002268-
Unlock trial analytics

Study Design & Arms

PurposeTREATMENT

Interventions

NameTypeDescription
SevirumabDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria Concurrent Medication: Allowed: * Zidovudine (AZT) \< 600 mg/day. * Experimental maintenance or prophylactic therapy with an approved therapeutic agent for a non-viral opportunistic infection. * Trimethoprim / sulfamethoxazole (TMP / SMX). * Pyrimethamine / sulfadoxine. * Aeros...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Sevirumab

What is Sevirumab used for?

Sevirumab is an investigational drug being studied for Cytomegalovirus Infections and Cytomegalovirus Retinitis. It is in Phase 1 clinical development. The drug is being developed by Novartis AG (NVS).

What does Sevirumab target?

Sevirumab is a human anti-cytomegalovirus monoclonal antibody. It is designed to target cytomegalovirus, the virus responsible for the infections it is being studied against. The drug is being evaluated for its safety and antiviral effects in patients with CMV infections.

Who makes Sevirumab?

Sevirumab is being developed by Novartis AG, a pharmaceutical company traded on the stock exchange under the ticker symbol NVS. The drug is currently in Phase 1 clinical development for cytomegalovirus infections.

What phase is Sevirumab in?

Sevirumab is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials have been completed to assess its safety and tolerance in patients with cytomegalovirus infections.

What clinical trials is Sevirumab in?

Sevirumab has been studied in two completed Phase 1 clinical trials: NCT00002016 and NCT00002268. These trials assessed the safety and antiviral effects of escalating doses of the drug in patients with CMV retinitis and CMV viremia or viruria, respectively.

Is Sevirumab the same as SDZ MSL-109?

Yes, Sevirumab is also known as SDZ MSL-109. In clinical trials, the drug was referred to as a human anti-cytomegalovirus monoclonal antibody (SDZ MSL-109). Both names refer to the same investigational drug being developed by Novartis.